CoChat
Sign Up
Cited by 31Systemic Lupus Erythematosus ResearchT-cell and B-cell ImmunologyRheumatoid Arthritis Research and Therapies

The Role of a Key Transcription Factor PU.1 in Autoimmune Diseases

Open access
Fang, Yilong, Chen, Weile, Li, Zhe, Chen, Yu, Wu, Xuming, Zhu, Xiangling, Wang, Huihui, Chen, Xiaochun +8 more·2022·Frontiers in Immunology
DOI 10.3389/fimmu.2022.1001201PMC PMC9557192
Open this paper in CoChat — free accountOpen PDF

Abstract

PU.1, a transcription factor member of the E26 transformation-specific family, affects the function of a variety of immune cells in several physiological and pathological conditions. Previous studies studying the role of PU.1 in pathological conditions have mainly focused on immune system-related cancers, and a series of articles have confirmed that PU.1 mutation can induce a variety of immune cell-related malignancies. The underlying mechanism has also been extensively validated. However, the role of PU.1 in other major immune system-related diseases, namely, systemic autoimmune diseases, is still unclear. It was only in recent years that researchers began to gradually realize that PU.1 also played an important role in a variety of autoimmune diseases, such as rheumatoid arthritis (RA), experimental autoimmune encephalomyelitis (EAE) and systemic lupus erythematosus (SLE). This review article summarizes the findings of recent studies that investigated the role of PU.1 in various autoimmune diseases and the related underlying mechanisms. Furthermore, it presents new ideas and provides insight into the role of PU.1 as a potential treatment target for autoimmune diseases and highlights existing research problems and future research directions in related fields.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2022.1001201

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PU.1 functions as an immune activator by inducing the expression of IL-9 and CD80.

    “PU.1 also functions as an immune activator by inducing the expression of IL‐9 and CD80 [58, 59, 60].”

    From Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease (2026) · cites this paper as [60]

    The ‘PU.1 in rheumatoid arthritis’ section (page unavailable) says PU.1 binds the IL-9 promoter and is essential for Th9-related inflammation, supporting the IL-9 and immune-activation part of the claim. Our copy does not report PU.1 inducing CD80 expression (searched: CD80 and PU.1 expression). (LLM, conf=0.84)

    Experimental — accuracy not yet measured

  • Pathogenic myeloid cell activity in the context of autoimmunity and chronic inflammatory disease has been attributed to PU.1-dependent gene programs.

    “Of note, pathogenic myeloid cell activity in the context of autoimmunity and chronic inflammatory disease has been attributed to PU.1-dependent gene programs (Fang et al., 2022)”

    From PU.1 is required to restrain myelopoiesis during chronic inflammatory stress (2023) · cites this paper as Fang et al., 2022

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 34

  1. [1]Hosokawa H Rothenberg EV. How transcription factors drive choice of the T cell fate. Nat Rev Immunol (2021) 21: 162–76. doi: 10.1038/s41577-020-00426-6 PMC7933071 32918063 · DOI
  2. [5]Carotta S Wu L Nutt SL. Surprising new roles for PU.1 in the adaptive immune response. Immunol Rev (2010) 238: 63– 75. doi: 10.1111/j.1600-065X.2010.00955.x 20969585 · DOI · Paper page
  3. [6]Yoon H Jeremy M. Boss. PU.1 binds to a distal regulatory element that is necessary for b-cell specific expression of the class II transactivator. J Immunol (2010) 184: 5018–28. doi: 10.4049/jimmunol.1000079.PU.1 PMC3472449 20363966 · DOI
  4. [7]Joo M Kwon M Azim AC Sadikot RT Timothy S Christman JW. Genetic determination of the role of PU.1 in macrophage gene expression. Biochem Biophys Res Commun (2008) 372: 97– 102. doi: 10.1016/j.bbrc.2008.04.189 18485892 PMC2494535 · DOI
  5. [8]Yashiro T Takeuchi H Nakamura S Tanabe A Hara M Uchida K. PU.1 plays a pivotal role in dendritic cell migration from the periphery to secondary lymphoid organs via regulating CCR7 expression. FASEB J (2019) 33: 11481–91. doi: 10.1096/fj.201900379RR 31314592 · DOI
  6. [10]Kastner P Chan S. PU.1: A crucial and versatile player in hematopoiesis and leukemia. Int J Biochem Cell Biol (2008) 40: 22–7. doi: 10.1016/j.biocel.2007.01.026 17374502 · DOI · Paper page
  7. [12]Shapira Y Agmon-Levin N Shoenfeld Y. Geoepidemiology of autoimmune rheumatic diseases. Nat Rev Rheumatol (2010) 6: 468–76. doi: 10.1038/nrrheum.2010.86 20567251 · DOI
  8. [13]Alivernini S Kurowska-Stolarska M Tolusso B Benvenuto R Elmesmari A Canestri S. MicroRNA-155 influences b-cell function through PU.1 in rheumatoid arthritis. Nat Commun (2016) 7. doi: 10.1038/ncomms12970 PMC5052655 27671860 · DOI
  9. [14]Xie Z Qu Y Shen P Wang B Wei K Du B. PU.1 attenuates TNF-α-induced proliferation and cytokine release of rheumatoid arthritis fibroblast-like synoviocytes by regulating miR-155 activity. Mol Med Rep (2018) 17: 8349–56. doi: 10.3892/mmr.2018.8920 29693176 · DOI
  10. [15]Park SY Lee SW Baek SH Lee CW Lee WS Rhim BY. Suppression of PU.1-linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis. Br J Pharmacol (2013) 168: 1401–11. doi: 10.1111/bph.12021 PMC3596645 23072581 · DOI
  11. [16]Park SY Lee SW Kim HY Lee SY Lee WS Hong KW. SIRT1 inhibits differentiation of monocytes to macrophages: amelioration of synovial inflammation in rheumatoid arthritis. J Mol Med (2016) 94: 921–31. doi: 10.1007/s00109-016-1402-7 26956118 · DOI
  12. [17]Korneev KV Sviriaeva EN Mitkin NA Gorbacheva AM Uvarova AN Ustiugova AS. Minor c allele of the SNP rs7873784 associated with rheumatoid arthritis and type-2 diabetes mellitus binds PU.1 and enhances TLR4 expression. Biochim Biophys Acta - Mol Basis Dis (2020) 1866. doi: 10.1016/j.bbadis.2019.165626 31785408 · DOI
  13. [18]Ciccia F Guggino G Rizzo A Manzo A Vitolo B La MMP. Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis. Rheumatol (United Kingdom) (2015) 54: 2264–72. doi: 10.1093/rheumatology/kev252 26178600 · DOI
  14. [20]Talotta R Berzi A Doria A Batticciotto A Ditto MC Atzeni F. The immunogenicity of branded and biosimilar infliximab in rheumatoid arthritis according to Th9-related responses. Int J Mol Sci (2017) 18. doi: 10.3390/ijms18102127 PMC5666809 29023386 · DOI
  15. [21]Shakerian L Ghorbani S Talebi F Noorbakhsh F. MicroRNA-150 targets PU.1 and regulates macrophage differentiation and function in experimental autoimmune encephalomyelitis. J Neuroimmunol (2018) 323: 167–74. doi: 10.1016/j.jneuroim.2018.06.010 30196828 · DOI
  16. [24]Li H Nourbakhsh B Ciric B Zhang G-X Rostami A. Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population. J Immunol (2010) 185: 4095–100. doi: 10.4049/jimmunol.1000986 PMC2978501 20805418 · DOI
  17. [25]Wang J Qi Y Niu X Tang H Meydani SN Wu D. Dietary naringenin supplementation attenuates experimental autoimmune encephalomyelitis by modulating autoimmune inflammatory responses in mice. J Nutr Biochem (2018) 54: 130–9. doi: 10.1016/j.jnutbio.2017.12.004 29331869 · DOI
  18. [26]Xiang N Fang X Sun XG Zhou YB Ma Y Zhu C. Expression profile of PU.1 in CD4+T cells from patients with systemic lupus erythematosus. Clin Exp Med (2021) 21: 621–32. doi: 10.1007/s10238-021-00717-9 33966135 · DOI
  19. [27]Aboelenein HR Hamza MT Marzouk H Youness RA Rahmoon M Salah S. Reduction of CD19 autoimmunity marker on b cells of paediatric SLE patients through repressing PU.1/TNF-α/BAFF axis pathway by miR-155. Growth Factors (2017) 35: 49– 60. doi: 10.1080/08977194.2017.1345900 28683581 · DOI
  20. [29]Patrick DM de la Visitación N Krishnan J Chen W Ormseth MJ Stein CM. Isolevuglandins disrupt PU.1 mediated C1q expression and promote autoimmunity and hypertension in systemic lupus erythematosus. JCI Insight (2022) 7: 1– 24. doi: 10.1172/jci.insight.136678 PMC9310530 35608913 · DOI
  21. [30]Ouyang H Shi Y Liu Z Feng S Li L Su N. Increased interleukin-9 and CD4+IL-9+ T cells in patients with systemic lupus erythematosus. Mol Med Rep (2013) 7: 1031–7. doi: 10.3892/mmr.2013.1258 23291628 · DOI
  22. [31]Sheng Y Zhang J Li K Wang H Wang W Wen L. Bach2 overexpression represses Th9 cell differentiation by suppressing IRF4 expression in systemic lupus erythematosus. FEBS Open Bio (2021) 11: 395– 403. doi: 10.1002/2211-5463.13050 PMC7876501 33249782 · DOI
  23. [32]Umazume A Kezuka T Matsuda R Usui Y Takahashi H Yamakawa N. Role of PU.1 expression as an inflammatory marker in experimental autoimmune uveoretinitis. Ocul Immunol Inflammation (2018) 26: 951–63. doi: 10.1080/09273948.2017.1299867 28448751 · DOI
  24. [33]Watt S Vasquez L Walter K Mann AL Kundu K Chen L. Genetic perturbation of PU.1 binding and chromatin looping at neutrophil enhancers associates with autoimmune disease. Nat Commun (2021) 12: 1– 12. doi: 10.1038/s41467-021-22548-8 33863903 PMC8052402 · DOI · Paper page
  25. [34]Felton JM Bouffi C Schwartz JT Schollaert KL Malik A Vallabh S. Aiolos regulates eosinophil migration into tissues. Mucosal Immunol (2021) 14: 1271–81. doi: 10.1038/s41385-021-00416-4 PMC8542574 34341502 · DOI
  26. [35]Gerlach K Hwang Y Nikolaev A Atreya R Dornhoff H Steiner S. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol (2014) 15: 676–86. doi: 10.1038/ni.2920 24908389 · DOI · Paper page
  27. [36]Shao Q Wang Y Liu Z Liu H Wang Y Zhao Y. Th9 cells in peripheral blood increased in patients with immune-related pancytopenia. J Immunol Res (2020) 2020. doi: 10.1155/2020/6503539 PMC7222599 32455141 · DOI
  28. [37]Alter-Koltunoff M Ehrlich S Dror N Azriel A Eilers M Hauser H. Nramp1-mediated innate resistance to intraphagosomal pathogens is regulated by IRF-8, PU.1, and miz-1. J Biol Chem (2003) 278: 44025–32. doi: 10.1074/jbc.M307954200 12904288 · DOI
  29. [38]Chen Q Mang G Wu J Sun P Li T Zhang H. Circular RNA circSnx5 controls immunogenicity of dendritic cells through the miR-544/SOCS1 axis and PU.1 activity regulation. Mol Ther (2020) 28: 2503–18. doi: 10.1016/j.ymthe.2020.07.001 PMC7646215 32681834 · DOI
  30. [39]Meng Y Li J Ye Z Yin Z Sun Q Liao Z. MicroRNA-148a facilitates inflammatory dendritic cell differentiation and autoimmunity by targeting MAFB. JCI Insight (2020) 5. doi: 10.1172/jci.insight.133721 PMC7205423 32213710 · DOI
  31. [40]Wang XQ Hu GH Kang HY Shen Y Ke X Hong SL. High frequency of t helper type 9 cells in chinese patients with allergic rhinitis. Asian Pacific J Allergy Immunol (2015) 33: 301–7. doi: 10.12932/AP0609.33.4.2015 26708394 · DOI
  32. [41]Chowdhury K Kumar U Das S Chaudhuri J Kumar P Kanjilal M. Synovial IL-9 facilitates neutrophil survival, function and differentiation of Th17 cells in rheumatoid arthritis. Arthritis Res Ther (2018) 20: 1– 12. doi: 10.1186/s13075-017-1505-8 29382374 PMC5791733 · DOI
  33. [42]Chen Z Fan R Liang J Xiao Z Dang J Zhao J. NFIL3 deficiency alleviates EAE through regulating different immune cell subsets. J Adv Res (2021) 39: 225–35. doi: 10.1016/j.jare.2021.10.011 PMC9263648 35777910 · DOI
  34. [43]Guggino G Pio La Manna M Di Liberto D Lo Pizzo M Grasso G Schinocca C. Interleukin 9 neutralisation reduces collagen-induced arthritis severity in mouse models. Clin Exp Rheumatol (2022) 1. doi: 10.55563/clinexprheumatol/chima7 35616583 · DOI

Cited by

Sorted by citations

Authors
Fang, Y., Chen, W., Li, Z., Chen, Y., Wu, X., Zhu, X., Wang, H., Chen, X., Liang, Q., Huang, J., Han, X., Hong, W., Wang, X., Wei, W., Yu, Z., & Tu, J.
Affiliations
  • Anhui Medical University (CN)
  • Southern Medical University (CN)
  • Shenzhen University Health Science Center (CN)
  • First Affiliated Hospital of Anhui Medical University (CN)
Corresponding author
  • Wei, Wei
  • Yu, Zhiying
  • Tu, Jiajie
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2022-09-29
Volume
13
Pages
1001201-1001201
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2022.1001201
PMC
PMC9557192
OpenAlex
W4303184314
Cited by
31
References
9
Citations by year
2026: 10 · 2025: 11 · 2024: 5 · 2023: 5
FWCI
0.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Anhui Medical University (2020xkjT009)
  • Shenzhen Municipal Science and Technology Innovation Council (JCYJ20210324102806018, JCYJ20210324103001003)
  • Sanming Project of Medicine in Shenzhen (JCYJ20210324102806018, SZSM201812041)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Keywords
PU.1, ETS transcription factors, autoimmune disease, rheumatoid arthritis, experimental autoimmune encephalomyelitis, systemic lupus erythematosus, immune cell function, therapeutic target
MeSH terms
Proto-Oncogene Protein Spi-1, Animals, Encephalomyelitis, Autoimmune, Experimental, Lupus Erythematosus, Systemic, Neoplasms, Proto-Oncogene Proteins, Transcription Factors, Trans-Activators

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review